NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC

NCT07318636 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Resectable Non-small Cell Lung Cancer

Interventions

DRUG: PD-1 antibody
BIOLOGICAL: NK010

Sponsor

The First Affiliated Hospital of Guangzhou Medical University

Collaborators

[object Object]